Entrada Therapeutics, Inc.

NasdaqGM:TRDA Voorraadrapport

Marktkapitalisatie: US$619.3m

Entrada Therapeutics Beheer

Beheer criteriumcontroles 4/4

Entrada Therapeutics' CEO is Dipal Doshi, appointed in Aug 2017, has a tenure of 7.25 years. total yearly compensation is $3.74M, comprised of 15.7% salary and 84.3% bonuses, including company stock and options. directly owns 0.35% of the company’s shares, worth $2.18M. The average tenure of the management team and the board of directors is 3.6 years and 3.7 years respectively.

Belangrijke informatie

Dipal Doshi

Algemeen directeur

US$3.7m

Totale compensatie

Percentage CEO-salaris15.7%
Dienstverband CEO7.3yrs
Eigendom CEO0.4%
Management gemiddelde ambtstermijn3.6yrs
Gemiddelde ambtstermijn bestuur3.7yrs

Recente managementupdates

Recent updates

There Is A Reason Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Price Is Undemanding

Oct 17
There Is A Reason Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Price Is Undemanding

Analysts' Revenue Estimates For Entrada Therapeutics, Inc. (NASDAQ:TRDA) Are Surging Higher

Aug 23
Analysts' Revenue Estimates For Entrada Therapeutics, Inc. (NASDAQ:TRDA) Are Surging Higher

Entrada Therapeutics: A Complicated Tale

Jun 16

Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Shares Bounce 30% But Its Business Still Trails The Industry

May 29
Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Shares Bounce 30% But Its Business Still Trails The Industry

These Analysts Just Made A Massive Downgrade To Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) EPS Forecasts

Mar 19
These Analysts Just Made A Massive Downgrade To Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) EPS Forecasts

This Just In: Analysts Are Boosting Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) Outlook for Next Year

Nov 09
This Just In: Analysts Are Boosting Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) Outlook for Next Year

Need To Know: Analysts Are Much More Bullish On Entrada Therapeutics, Inc. (NASDAQ:TRDA)

May 26
Need To Know: Analysts Are Much More Bullish On Entrada Therapeutics, Inc. (NASDAQ:TRDA)

Earnings Miss: Entrada Therapeutics, Inc. Missed EPS And Analysts Are Revising Their Forecasts

May 14
Earnings Miss: Entrada Therapeutics, Inc. Missed EPS And Analysts Are Revising Their Forecasts

Will Entrada Therapeutics (NASDAQ:TRDA) Spend Its Cash Wisely?

Mar 08
Will Entrada Therapeutics (NASDAQ:TRDA) Spend Its Cash Wisely?

We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate

Sep 11
We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate

Entrada Therapeutics GAAP EPS of -$0.74 misses by $0.02

Aug 11

We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate

May 28
We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate

We Think Entrada Therapeutics (NASDAQ:TRDA) Can Afford To Drive Business Growth

Jan 31
We Think Entrada Therapeutics (NASDAQ:TRDA) Can Afford To Drive Business Growth

Analyse CEO-vergoeding

Hoe is Dipal Doshi's beloning veranderd ten opzichte van Entrada Therapeutics's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

US$104m

Mar 31 2024n/an/a

US$23m

Dec 31 2023US$4mUS$585k

-US$7m

Sep 30 2023n/an/a

-US$22m

Jun 30 2023n/an/a

-US$82m

Mar 31 2023n/an/a

-US$80m

Dec 31 2022US$3mUS$565k

-US$95m

Sep 30 2022n/an/a

-US$88m

Jun 30 2022n/an/a

-US$78m

Mar 31 2022n/an/a

-US$64m

Dec 31 2021US$6mUS$425k

-US$51m

Sep 30 2021n/an/a

-US$41m

Jun 30 2021n/an/a

-US$34m

Mar 31 2021n/an/a

-US$29m

Dec 31 2020US$906kUS$385k

-US$27m

Compensatie versus markt: Dipal's total compensation ($USD3.74M) is about average for companies of similar size in the US market ($USD3.24M).

Compensatie versus inkomsten: Dipal's compensation has been consistent with company performance over the past year.

CEO

Dipal Doshi (48 yo)

7.3yrs

Tenure

US$3,735,466

Compensatie

Mr. Dipal Doshi serves as Director of The Children's Health Fund. He serves as Director of Ashibio, Inc since September 2024. Mr. Doshi has been Chief Executive Officer and Director of Entrada Therapeutics...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Dipal Doshi
CEO & Director7.3yrsUS$3.74m0.35%
$ 2.2m
Nathan Dowden
President & COO5yrsUS$1.49m0.36%
$ 2.2m
Natarajan Sethuraman
President of Research & Developmentless than a yearUS$1.49m0.31%
$ 1.9m
Kory Wentworth
CFO & Treasurer4yrsgeen gegevens0.22%
$ 1.3m
Jared Cohen
General Counsel4.6yrsgeen gegevensgeen gegevens
Kerry Robert
Senior Vice President of People3.3yrsgeen gegevensgeen gegevens
Karla MacDonald
Chief Corporate Affairs Officer2.3yrsgeen gegevensgeen gegevens
Kevin Healy
Senior Vice President of Regulatory Affairsless than a yeargeen gegevensgeen gegevens

3.6yrs

Gemiddelde duur

50.5yo

Gemiddelde leeftijd

Ervaren management: TRDA's management team is considered experienced (3.6 years average tenure).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Dipal Doshi
CEO & Director7.3yrsUS$3.74m0.35%
$ 2.2m
Peter Kim
Director3.9yrsUS$192.12k0.30%
$ 1.8m
Mary Thistle
Industry Leader & Independent Director3.5yrsUS$211.18k0%
$ 0
Kush Parmar
Independent Chairman of the Board8.1yrsUS$237.58k0%
$ 0
Bernhardt G. Zeiher
Industry Leader & Independent Director1.6yrsUS$334.02k0%
$ 0
Gina Chapman
Independent Director1.2yrsUS$341.88k0%
$ 0

3.7yrs

Gemiddelde duur

58.5yo

Gemiddelde leeftijd

Ervaren bestuur: TRDA's board of directors are considered experienced (3.7 years average tenure).